International, randomized, open-label, phase 3 trial of paclitaxel/carboplatin plus PF-3512676 versus paclitaxel/carboplatin alone as first-line treatment of patients with advanced non-small cell lung cancer

Trial Profile

International, randomized, open-label, phase 3 trial of paclitaxel/carboplatin plus PF-3512676 versus paclitaxel/carboplatin alone as first-line treatment of patients with advanced non-small cell lung cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2015

At a glance

  • Drugs Agatolimod; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 06 Apr 2015 Last checked against the ClinicalTrials.gov record.
    • 10 Nov 2008 Actual patient number identified as 828 from ClinicalTrials.gov.
    • 10 Nov 2008 Actual trial completion date identified as July 2008 from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top